Abbott's pivotal trial results for Portico boosted by new delivery ... | 合法醫療器材資訊網

2020年9月22日 — ... SM, FACC; Summary Reviewer: Kim A. Eagle, MD, MACC; Trial Sponsor: Abbott ... The PORTICO IDE trial showed that TAVR with the self-expanding ... Of note, the Food and Drug Administration (FDA) stopped the PORTICO IDE trial ... Jun 10, 20 Read More

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) ... Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First ... Read More

2019年9月27日 — The Portico IDE study found that 30-day safety and one-year ... of the Portico TAVI system (Abbott) compared with FDA-approved and ... Read More

2020年3月6日 — With the approval, physicians implanting Portico can benefit from ... The new FlexNav delivery system demonstrates Abbott's commitment to ... Read More

Portico is the first fully resheathable, repositionable, and retrievable aortic valve used for transcatheter aortic valve implantation (TAVI). Read More

2019年9月30日 — Portico NG is in a clinical trial that started in August and is expected to complete in November 2020 with a potential FDA approval to follow in ... Read More

2019年9月30日 — These findings suggest the Portico valve may provide an additional transcatheter. ... valve (Abbott) and a first-generation delivery system or any FDA-approved ... New-generation TAVR system approved for low-risk patients Read More

... risk patient population to support CE (Conformité Européenne) Mark and FDA approval. ... The Portico NG Approval study will be conducted as a prospective, multi-center, ... Contact: Mira Tissari, +32 470 47 0942, [email protected]. Read More